Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apitegromab in infants with spinal muscular atrophy receiving SMN-targeted therapy
NL-OMON60681Phase 2Recruiting
- Sponsor
- Scholar Rock
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apitegromab in spinal muscular atrophy (SMA), sponsored by Scholar Rock. Primary endpoints: Population pharmacokinetic model parameters, Serum apitegromab and total latent myostatin concentrations and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
apitegromab
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NL-OMON60681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60681.